Summary
InDex Pharmaceuticals Holding AB (InDex Pharmaceuticals) is a pharmaceutical company that offers treatments for immunological diseases. The company’s lead compound cobitolimod, currently in the phase 2 stage, is intended for the treatment of moderate to severe treatment active refractory ulcerative colitis. Its preclinical products include DIMS 9054, and DIMS 9059, which are intended for treating resistant pulmonary inflammation and cancer. InDex Pharmaceuticals offers dibicol, a PCR-based method that monitors proprietary biomarkers used for ulcerative colitis. The company conducts clinical studies in the Czech Republic, France, Germany, Hungary, Spain, Russia, Italy, Poland, Romania, Serbia, Sweden, and Ukraine. InDex Pharmaceuticals is headquartered in Stockholm, Sweden.

InDex Pharmaceuticals Holding AB Key Recent Developments

Apr 07,2021: InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe
Mar 30,2021: InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis
Mar 10,2021: InDex Pharmaceuticals presents at Barclays Global Healthcare Conference and Carnegie Nordic Virtual Healthcare Seminar
Nov 25,2020: InDex Pharmaceuticals Holding: interim report January – September 2020
Aug 26,2020: InDex Pharmaceuticals Holding : Interim report January – June 2020

This comprehensive SWOT profile of InDex Pharmaceuticals Holding AB provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of InDex Pharmaceuticals Holding AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.